Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report

INTRODUCTION: Cabozantinib (XL-184) is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2 that has been shown to reduce tumor growth, metastasis, and angiogenesis. After the promising results from the METEOR and CABOSUN trials, cabozantinib was approved for use in the first- a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilen, Mehmet A., Jiang, James F., Jansen, Caroline S., Brown, Jacqueline T., Harik, Lara R., Sekhar, Aarti, Kissick, Haydn, Maithel, Shishir K., Kucuk, Omer, Carthon, Bradley, Master, Viraj A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882722/
https://www.ncbi.nlm.nih.gov/pubmed/33598435
http://dx.doi.org/10.3389/fonc.2020.622134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882722/
https://www.ncbi.nlm.nih.gov/pubmed/33598435
http://dx.doi.org/10.3389/fonc.2020.622134

Ejemplares similares